Pre-screening Survey for Metabolic, Cardiovascular, Obesity, Mental Health, and Endocrine Trial Eligibility (DOVE-MET-COME-100)

What this Trial Is About

Researchers are conducting a prescreening survey study called DOVE-MET-COME-100 to identify adults who may qualify for future clinical trials focused on metabolic, cardiovascular, obesity, mental health, and endocrine conditions. This observational study aims to collect detailed health and demographic information without testing any investigational treatments. The goal is to build a structured database of individuals with metabolic, cardiovascular, endocrine, and psychiatric risk factors to support upcoming industry-sponsored trials. Participants will undergo screening procedures including health questionnaires and laboratory tests such as blood work for metabolic and biomarker analysis, including Hemoglobin A1c, lipid panel, and liver and kidney function tests. There are no treatment interventions in this study; instead, participants will be evaluated for potential eligibility in future sub-studies through clinical evaluations and medical history reviews conducted by a physician. During the study, participants will provide informed consent and complete surveys on demographics, medical history, current health conditions, and symptoms. Basic health information such as vital signs, urine drug tests, blood samples, and pregnancy tests (if applicable) will be collected. A physician will review the medical history and may contact the participant's current doctors or pharmacies to gather additional information. The main measure of interest is the number of participants who express interest in future clinical research over five years while maintaining a detailed database of pre-screened individuals. The study is expected to last up to five years.

Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.